OPKO Health OPK shares were trading higher on Thursday after the company and Pfizer announced C0311002, its Phase 3 study evaluating somatrogon, met its primary endpoint.
Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation.
OPKO Health shares traded up 3.41% to $4.55 on Thursday. The stock has a 52-week high of $6.47 and a 52-week low of $1.12.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in